Modulation of tumor immunity by therapeutic monoclonal antibodies

Cancer and Metastasis Reviews

Volumn 30, Issue 1, 2011, Pages 111-124

  Abès, Riad ^a,b   Teillaud, Jean Luc ^a,b  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Adaptive immunity; Cancer; Fcgamma receptor; Immunomodulation; Immunotherapy; Monoclonal antibody

Indexed keywords

ALEMTUZUMAB; BEVACIZUMAB; CATUMAXOMAB; CETUXIMAB; EDRECOLOMAB; GEMTUZUMAB; IBRITUMOMAB TIUXETAN; METUXIMAB; MONOCLONAL ANTIBODY; NIMOTUZUMAB; OFATUMUMAB; PANITUMUMAB; RITUXIMAB; TOSITUMOMAB; TRASTUZUMAB; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PATIENT; DRUG EFFICACY; DRUG MECHANISM; HUMAN; IMMUNOMODULATION; IN VIVO STUDY; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

ANIMALS; ANTIBODIES, MONOCLONAL; HUMANS; IMMUNITY; IMMUNOTHERAPY; NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 79952281910     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10555-011-9282-3     Document Type: Article

References (124)

1. G Klein 1973 Epstein-Barr virus (EBV)-induced transformation of human lymphoid cells and immunosurveillance against lymphoma development Annales d'Immunologie (Paris) 124 391 405 1:STN:280:DyaE2c%2FosVOrsg%3D%3D
2. World Health Organization (1987) Genital human papillomavirus infections and cancer: memorandum from a WHO meeting. Bulletin of the World Health Organization 65: 817-827
3. F Pagès A Berger M Camus F Sanchez-Cabo A Costes R Molidor, et al. 2005 Effector memory T cells, early metastasis, and survival in colorectal cancer The New England Journal of Medicine 353 2654 2666 16371631 (Pubitemid 41817714)
4. J Galon A Costes F Sanchez-Cabo A Kirilovsky B Mlecnik C Lagorce-Pagès, et al. 2006 Type, density, and location of immune cells within human colorectal tumors predict clinical outcome Science 313 1960 1964 17008531 1:CAS:528:DC%2BD28XhtVSnsrnK (Pubitemid 44498003)
5. M-C Dieu-Nosjean M Antoine C Danel D Heudes M Wislez V Poulot, et al. 2008 Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures Journal of Clinical Oncology 26 4410 4417 18802153 1:CAS:528:DC%2BD1cXht1ejur7F
6. O Türeci U Sahin M Pfreundschuh 1997 Serological analysis of human tumor antigens: molecular definition and implications Molecular Medicine Today 3 342 349 9269687 (Pubitemid 28119269)
7. YT Chen MJ Scanlan U Sahin O Türeci AO Gure S Tsang, et al. 1997 A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening Proceedings of the National Academy of Sciences of the United States of America 94 1914 1918 9050879 1:CAS:528:DyaK2sXhslegu70%3D (Pubitemid 27113936)
8. T Boon PG Coulie BJ van den Eynde P van der Bruggen 2006 Human T cell responses against melanoma Annual Review of Immunology 24 175 208 16551247 1:CAS:528:DC%2BD28XkvFSqt7o%3D
9. MJ Glennie RR French MS Cragg RP Taylor 2007 Mechanisms of killing by anti-CD20 monoclonal antibodies Molecular Immunology 44 3823 3837 17768100 1:CAS:528:DC%2BD2sXpsl2htr4%3D (Pubitemid 47332625)
10. R Abès CA Dutertre L Agnelli JL Teillaud 2009 Activating and inhibitory Fcgamma receptors in immunotherapy: being the actor or being the target Expert Review of Clinical Immunology 5 735 747 20477693
11. T Takai M Li D Sylvestre R Clynes JV Ravetch 1994 FcR gamma chain deletion results in pleiotrophic effector cell defects Cell 76 519 529 8313472 1:CAS:528:DyaK2cXhvV2ht7s%3D (Pubitemid 24064172)
12. RA Clynes TL Towers LG Presta JV Ravetch 2000 Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets Natural Medicines 6 443 446 1:CAS:528:DC%2BD3cXisVOru7Y%3D (Pubitemid 30208162)
13. Z Zhang M Zhang CK Goldman JV Ravetch TA Waldmann 2003 Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H Cancer Research 63 6453 6457 14559836 1:CAS:528:DC%2BD3sXotV2is7w%3D (Pubitemid 37255196)
14. M Zhang Z Zhang K Garmestani CK Goldman JV Ravetch MW Brechbiel, et al. 2004 Activating Fc receptors are required for antitumor efficacy of the antibodies directed toward CD25 in a murine model of adult T-cell leukemia Cancer Research 64 5825 5829 15313926 1:CAS:528:DC%2BD2cXmslaks78%3D (Pubitemid 39095583)
15. G Cartron L Dacheux G Salles P Solal-Celigny P Bardos P Colombat, et al. 2002 Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene Blood 99 754 758 11806974 1:CAS:528:DC%2BD38XhtVals7k%3D (Pubitemid 34525533)
16. WK Weng R Levy 2003 Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma Journal of Clinical Oncology 21 3940 3947 12975461 1:CAS:528:DC%2BD2cXpsVajsb8%3D (Pubitemid 46606207)
17. M Ghielmini K Rufibach G Salles L Leoncini-Franscini C Léger-Falandry S Cogliatti, et al. 2005 Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK) Annals of Oncology 16 1675 1682 16030029 1:STN:280:DC%2BD2MvpvFKitA%3D%3D (Pubitemid 41510143)
18. SP Treon M Hansen AR Branagan S Verselis C Emmanouilides E Kimby, et al. 2005 Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstro m's macroglobulinemia Journal of Clinical Oncology 23 474 481 15659493 1:CAS:528:DC%2BD2MXitVartro%3D (Pubitemid 46224224)
19. DH Kim HD Jung JG Kim JJ Lee DH Yang YH Park, et al. 2006 FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma Blood 108 2720 2725 16609067 1:CAS:528: DC%2BD28XhtFWgtLzM
20. W Zhang M Gordon AM Schultheis DY Yang F Nagashima M Azuma, et al. 2007 FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab Journal of Clinical Oncology 25 3712 3718 17704420 1:CAS:528:DC%2BD2sXhtVeqt7fI (Pubitemid 47372612)
21. A Musolino N Naldi B Bortesi D Pezzuolo M Capelletti G Missale, et al. 2008 Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER- 2/neu-positive metastatic breast cancer Journal of Clinical Oncology 26 1789 1796 18347005 1:CAS:528:DC%2BD1cXmsFemsLg%3D
22. J Lejeune G Thibault D Ternant G Cartron H Watier M Ohresser 2008 Evidence for linkage disequilibrium between Fcgamma RIIIa-V158F and Fcgamma RIIa-H131R polymorphisms in white patients, and for an Fcgamma RIIIa-restricted influence on the response to therapeutic antibodies Journal of Clinical Oncology 26 5489 5491 18955438
23. F Bibeau E Lopez-Crapez F Di Fiore S Thezenas M Ychou F Blanchard, et al. 2009 Impact of FcgammaRIIa- FcgammaRIIIa polymorphism and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus Irinotecan. Journal of Clinical Oncology 27 1122 1129 19164213 1:CAS:528:DC%2BD1MXktVCisr8%3D
24. RA Miller DG Maloney R Warnke R Levy 1982 Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody The New England Journal of Medicine 306 517 522 6173751 1:STN:280:DyaL387isFehug%3D%3D (Pubitemid 12175745)
25. EM Rankin A Hekman R Somers W Ten Bokkel Huinink 1985 Treatment of two patients with B cell lymphoma with monoclonal anti-idiotype antibodies Blood 65 1373 1381 3873264 1:STN:280:DyaL2M3gtVaqsA%3D%3D (Pubitemid 15057943)
26. MH Tao R Levy 1993 Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma Nature 362 755 758 8469286 1:CAS:528:DyaK3sXitlWrt7c%3D (Pubitemid 23125980)
27. H Koprowski D Herlyn M Lubeck E DeFreitas HF Sears 1984 Human anti-idiotype antibodies in cancer patients: is the modulation of the immune response beneficial for the patient? Proceedings of the National Academy of Sciences of the United States of America 81 216 219 6582477 1:STN:280: DyaL2c7hvFCguw%3D%3D (Pubitemid 14180859)
28. + B cells is transiently inhibited by BCR-independent aggregation of Fc gamma RIIB Journal of Immunology 181 5350 5359 1:CAS:528:DC%2BD1cXhtF2hs7bK
29. A Regnault D Lankar V Lacabanne A Rodriguez C Théry M Rescigno, et al. 1999 Fcgamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization The Journal of Experimental Medicine 189 371 380 9892619 1:CAS:528:DyaK1MXmvFeltg%3D%3D (Pubitemid 29063258)
30. A Amigorena C Bonnerot 1999 Fc receptors for IgG and antigen presentation on MHC class I and class II molecules Seminars in Immunology 11 385 390 10625592 1:CAS:528:DC%2BD3cXhs1aitg%3D%3D (Pubitemid 30047500)
31. S Bolland JV Ravetch 2000 Spontaneous autoimmune disease in Fc(gamma)RIIB-deficient mice results from strain-specific epistasis Immunity 13 277 285 10981970 1:CAS:528:DC%2BD3cXmsVKnu7Y%3D
32. F Nimmerjahn JV Ravetch 2008 Fcgamma receptors as regulators of immune responses Nature Reviews. Immunology 8 34 47 18064051 1:CAS:528: DC%2BD2sXhsVKrsLnK
33. LM Weiner MV Dhodapkar S Ferrone 2009 Monoclonal antibodies for cancer immunotherapy Lancet 373 1033 1040 19304016 1:CAS:528:DC%2BD1MXjsVOnt7g%3D
34. J Greenwood M Clark H Waldmann 1993 Structural motifs involved in human IgG antibody effector functions European Journal of Immunology 23 1098 1104 8477804 1:CAS:528:DyaK3sXksVOis7s%3D (Pubitemid 23120172)
35. E Reff K Carner KS Chambers PC Chinn JE Leonard R Raab, et al. 1994 Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20 Blood 83 435 445 7506951 1:CAS:528:DyaK2cXhtVCnu70%3D (Pubitemid 24030569)
36. S Cooley LJ Burns T Repka JS Miller 1999 Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu Experimental Hematology 27 1533 1541 10517495 1:CAS:528:DyaK1MXmslWmtbk%3D (Pubitemid 29458428)
37. O Manches G Lui L Chaperot R Gressin JP Molens MC Jacob, et al. 2003 In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas Blood 101 949 954 12393572 1:CAS:528:DC%2BD3sXptVeqtA%3D%3D (Pubitemid 36139365)
38. S Dall'Ozzo S Tartas G Paintaud G Cartron P Colombat P Bardos, et al. 2004 Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship Cancer Research 64 4664 4669 15231679 (Pubitemid 38856941)
39. C de Romeuf CA Dutertre M Le Garff-Tavernier N Fournier C Gaucher A Glacet, et al. 2008 Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcgammaRIIIA/CD16 British Journal Haematology 140 635 643 (Pubitemid 351300917)
40. E Mössner P Brünker S Moser U Püntener C Schmidt S Herter, et al. 2010 Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct- and immune effector cell-mediated B-cell cytotoxicity Blood 115 4393 4402 20194898
41. A Savina S Amigorena 2007 Phagocytosis and antigen presentation in dendritic cells Immunological Reviews 219 143 156 17850487 1:CAS:528: DC%2BD2sXht1Cnt7zJ (Pubitemid 47390005)
42. KL Rock S Gamble L Rothstein 1990 Presentation of exogenous antigen with class I major histocompatibility complex molecules Science 249 918 921 2392683 1:CAS:528:DyaK3cXls12qurY%3D
43. SP Hart GJ Dougherty C Haslett I Dransfield 1997 CD44 regulates phagocytosis of apoptotic neutrophil granulocytes, but not apoptotic lymphocytes, by human macrophages Journal of Immunology 159 919 925 1:CAS:528:DyaK2sXksVyqs7c%3D (Pubitemid 127484246)
44. J Banchereau RM Steinman 1998 Dendritic cells and the control of immunity Nature 392 245 252 9521319 1:CAS:528:DyaK1cXitFWrsr8%3D (Pubitemid 28155090)
45. WR Heath GT Belz GMN Behrens CM Smith SP Forehan IA Parish, et al. 2004 Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens Immunological Reviews 199 9 26 15233723 1:CAS:528: DC%2BD2cXltFygs7s%3D (Pubitemid 38736761)
46. WL Hazenbos IA Heijnen D Meyer FM Hofhuis Renardel de Lavalette CR RE Schmidt, et al. 1998 Murine IgG1 complexes trigger immune effector functions predominantly via Fc gamma RIII (CD16) Journal of Immunoly 161 3026 3032 1:CAS:528:DyaK1cXmtVGnu7k%3D (Pubitemid 28425728)
47. D Meyer C Schiller J Westermann S Izui WL Hazenbos JS Verbeek, et al. 1998 FcgammaRIII (CD16)-deficient mice show IgG isotype-dependent protection to experimental autoimmune hemolytic anemia Blood 92 3902 3997
48. S Wernersson MC Karlsson J Dahlstrom R Mattsson JS Verbeek B Heyman 1999 IgG-mediated enhancement of antibody responses is low in Fc receptor gamma chain-deficient mice and increased in Fc gamma RII-deficient mice Journal of Immunology 163 618 622 1:CAS:528:DyaK1MXksVegtL0%3D (Pubitemid 29328064)
49. J Uchida Y Hamaguchi JA Oliver JV Ravetch JC Poe KM Haas, et al. 2004 The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy The Journal of Experimental Medicine 199 1659 1669 15210744 1:CAS:528: DC%2BD2cXltFKlurs%3D (Pubitemid 38821999)
50. V Minard-Colin Y Xiu JC Poe M Horikawa CM Magro Y Hamaguchi, et al. 2008 Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV Blood 112 1205 1213 18495955 1:CAS:528:DC%2BD1cXpvVOktrc%3D
51. E Oflazoglu IJ Stone KA Gordon IS Grewal N van Rooijen CL Law, et al. 2007 Macrophages contribute to the anti-tumor activity of the anti-CD30 antibody SGN-30 Blood 110 4370 4372 17909075 1:CAS:528:DC%2BD1cXot1Sk (Pubitemid 351377803)
52. E Oflazoglu IJ Stone L Brown KA Gordon N van Rooijen M Jonas, et al. 2009 Macrophages and Fc-receptor interactions contribute to the anti-tumour activities of the anti-CD40 antibody SGN-40 British Journal of Cancer 100 113 117 19066610 1:CAS:528:DC%2BD1MXjt1ShsQ%3D%3D
53. M Leidi E Gotti L Bologna E Miranda M Rimoldi A Sica, et al. 2009 M2 macrophages phagocytose rituximab- opsonized leukemic targets more efficiently than m1 cells in vitro Journal of Immunology 182 4415 4422 1:CAS:528: DC%2BD1MXjsVSju7k%3D
54. SA Beers CHT Chan RR French MS Cragg MJ Glennie 2010 CD20 as a target for therapeutic type I and II monoclonal antibodies Seminars in Hematology 47 107 114 20350657 1:CAS:528:DC%2BC3cXlslemtLk%3D
55. M Shibata-Koyama S Iida H Misaka K Mori K Yano K Shitara, et al. 2009 Nonfucosylated rituximab potentiates human neutrophil phagocytosis through its high binding for FcgammaRIIIb and MHC class II expression on the phagocytotic neutrophils Experimental Hematology 37 309 321 19218011 1:CAS:528: DC%2BD1MXhvFGrsbY%3D
56. NK Jerne 1974 Towards a network theory of the immune system Annales d'Immunologie 125 373 389 1:CAS:528:DyaE2cXhsVCju7s%3D
57. M Wettendorff D Iliopoulos M Tempero D Kay E DeFreitas H Koprowski, et al. 1989 Idiotypic cascades in cancer patients treated with monoclonal antibody CO17-1A Proceedings of the National Academy of Sciences of the United States of America 86 3787 3791 2786203 1:STN:280:DyaL1M3msVGjug%3D%3D (Pubitemid 19141830)
58. MJ Losman HJ Hansen RM Sharkey DM Goldenberg M Monestier 1991 Human response against NP-4, a mouse antibody to carcinoembryonic antigen: human anti-idiotype antibodies mimic an epitope on the tumor antigen Proceedings of the National Academy of Sciences of the United States of America 88 3421 3425 1707540 1:CAS:528:DyaK3MXktVKlsLY%3D (Pubitemid 21916633)
59. D2 antigen Journal of Immunology 151 3390 3398 1:CAS:528:DyaK3sXms1ymtLo%3D (Pubitemid 23282652)
60. BC Schultes RP Baum A Niesen AA Noujaim R Madiyalakan 1998 Anti-idiotype induction therapy: anti-CA125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1) Cancer Immunology, Immunotherapy 46 201 212 9671143 1:CAS:528:DyaK1cXkvV2itL4%3D (Pubitemid 28293820)
61. BM Bradt SJ DeNardo GR Mirick GL DeNardo 2003 Documentation of idiotypic cascade after Lym-1 radioimmunotherapy in a patient with non-Hodgkin's lymphoma: basis for extended survival? Clinical Cancer Research 9 4007 4012
62. S Hilchey O Hyrien T Mosmann A Livingstone J Friedberg F Young, et al. 2009 Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab Blood 113 3809 3812 19196657 1:CAS:528:DC%2BD1MXlt1yjsb0%3D
63. LW Kwak MJ Campbell DK Czerwinski S Hart RA Miller R Levy 1992 Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors The New England Journal of Medicine 327 1209 1215 1406793 1:STN:280:DyaK3s%2FisVOjtQ%3D%3D
64. D2 antibody therapy of stage 4 neuroblastoma Clinical Cancer Research 6 2653 2660 10914706 1:CAS:528:DC%2BD3cXlslentrc%3D (Pubitemid 30482100)
65. J Fagerberg JE Frödin H Wigzell H Mellstedt 1993 Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (ab1). I. May induction of ab1-reactive T cells and anti-anti-idiotypic antibodies (ab3) lead to tumor regression after mAb therapy? Cancer Immunology, Immunotherapy 37 264 270 8348565 1:STN:280:DyaK3szltFWlsg%3D%3D (Pubitemid 23300508)
66. J Fagerberg M Steinitz H Wigzell P Askelöf H Mellstedt 1995 Human anti-idiotypic antibodies induced a humoral and cellular immune response against a colorectal carcinoma-associated antigen in patients Proceedings of the National Academy of Sciences of the United States of America 92 4773 4777 7539133 1:STN:280:DyaK2M3otFGguw%3D%3D
67. A Mittelman ZJ Chen H Yang GY Wong S Ferrone 1992 Human high molecular weight melanoma- associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma Proceedings of the National Academy of Sciences of the United States of America 89 466 470 1731316 1:STN:280:DyaK387hsFKrsQ%3D%3D
68. D2 Clinical Cancer Research 4 1117 1124 9607568 1:CAS:528:DyaK1cXjt1yiuro%3D (Pubitemid 28213321)
69. D3 ganglioside antibodies Clinical Cancer Research 5 77 81 9918205 1:CAS:528:DyaK1MXhtVShtLo%3D (Pubitemid 29045180)
70. LG Durrant T Parsons R Moss I Spendlove G Carter F Carr 2001 Human anti-idiotypic antibodies can be good immunogens as they target Fc receptors on antigen-presenting cells allowing efficient stimulation of both helper and cytotoxic T-cell responses International Journal of Cancer 92 414 420 1:CAS:528:DC%2BD3MXjtVWiurw%3D (Pubitemid 32249720)
71. U Wagner S Köhler S Reinartz P Giffels J Huober K Renke, et al. 2001 Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. See The biology behind: K. A. Foon and M. Bhattacharya-Chatterjee, Are solid tumor anti-idiotype vaccines ready for prime time? Clinical Cancer Research 7 1112 1115 Clin Cancer Res 7: 1154-1162, 2001
72. JL Murray M Gillogly K Kawano CL Efferson JE Lee M Ross, et al. 2004 Fine specificity of high molecular weight-melanoma-associated antigen-specific cytotoxic T lymphocytes elicited by anti- idiotypic monoclonal antibodies in patients with melanoma Cancer Research 64 5481 5488 15289358 1:CAS:528:DC%2BD2cXmtF2lsro%3D (Pubitemid 39006572)
73. G Köhler C Milstein 1975 Continuous cultures of fused cells secreting antibodies of predefined specificity Nature 256 495 497 1172191
74. G Cartron H Watier J Golay P Solal-Celigny 2004 From the bench to the bedside: ways to improve rituximab efficacy Blood 104 2635 2642 15226177 1:CAS:528:DC%2BD2cXpslKjs70%3D (Pubitemid 39434941)
75. S Lim S Beers R French P Johnson M Glennie M Cragg 2010 Anti-CD20 monoclonal antibodies-historical and future perspectives Haematologica 115 5191 5201
76. R Abès E Gélizé WH Fridman JL Teillaud 2010 Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response Blood 116 926 934 20439625
77. LM Weiner R Surana S Wang 2010 Monoclonal antibodies: versatile platforms for cancer immunotherapy Nature Revue d'Immunologie 10 317 327 1:CAS:528:DC%2BC3cXltV2kurg%3D
78. KM Dhodapkar MV Dhodapkar 2005 Recruiting dendritic cells to improve antibody therapy of cancer Proceedings of the National Academy of Sciences of the United States of America 102 6243 6244 15851655 1:CAS:528: DC%2BD2MXktlygsLo%3D (Pubitemid 40617428)
79. A Sala I Gresser D Chassoux C Maury L Santodonato P Eid, et al. 1992 Inhibition of Friend leukemia cell visceral metastases by a new monoclonal antibody and role of the immune system of the host in its action Cancer Research 52 2880 2890 1581903 1:CAS:528:DyaK38XktVGqsbo%3D
80. DC Linehan PS Goedegebuure GE Peoples SO Rogers TJ Eberlein 1995 Tumor-specific and HLA-A2- restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer Journal of Immunology 155 4486 4491 1:CAS:528:DyaK2MXovFWlu7g%3D
81. GE Peoples PS Goedegebuure R Smith DC Linehan I Yoshino TJ Eberlein 1995 Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide Proceedings of the National Academy of Sciences of the United States of America 92 432 435 7831305 1:CAS:528:DyaK2MXjt12qsbo%3D
82. I Kawashima SJ Hudson V Tsai S Southwood K Takesako E Appella, et al. 1998 The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors Human Immunology 59 1 14 9544234 1:CAS:528:DyaK1cXhvVyhsLo%3D (Pubitemid 28141258)
83. Y Rongcun F Salazar-Onfray J Charo KJ Malmberg K Evrin H Maes, et al. 1999 Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas Journal of Immunology 163 1037 1044 1:CAS:528:DyaK1MXksVens7g%3D (Pubitemid 29328117)
84. R Sotiriadou SA Perez AD Gritzapis PA Sotiropoulou H Echner S Heinzel, et al. 2001 Peptide HER2(776-788) represents a naturally processed broad MHC class II-restricted T cell epitope British Journal of Cancer 85 1527 1534 11720440 1:CAS:528:DC%2BD38XkslemtQ%3D%3D (Pubitemid 34001585)
85. AD Gritzapis IF Voutsas E Lekka N Tsavaris I Missitzis P Sotiropoulou, et al. 2008 Identification of a novel immunogenic HLA-A*0201-binding epitope of HER-2/neu with potent antitumor properties Journal of Immunology 181 146 154 1:CAS:528:DC%2BD1cXnsVGjs7Y%3D
86. + cytotoxic T lymphocytes International Journal of Cancer 87 553 558 1:CAS:528: DC%2BD3cXlvVymsrY%3D (Pubitemid 30639816)
87. AD Gritzapis LG Mahaira SA Perez NT Cacoullos M Papamichail CN Baxevanis 2006 Vaccination with human HER- 2/neu (435-443) CTL peptide induces effective antitumor immunity against HER-2/neu-expressing tumor cells in vivo Cancer Research 66 5452 5460 16707474 1:CAS:528:DC%2BD28XksF2itrk%3D (Pubitemid 43844973)
88. + T cell-mediated antitumor responses by a helper HER-2/neu peptide linked to the Ii-Key moiety of the invariant chain International Journal of Cancer 121 2031 2041 1:CAS:528:DC%2BD2sXhtFSjsLzN (Pubitemid 47463167)
89. S Li J Yang FA Urban JN Macgregor DPM Hughes AE Chang, et al. 2008 Genetically engineered T cells expressing a HER2-specific chimeric receptor mediate antigen-specific tumor regression Cancer Gene Therapy 15 382 392 18292797 1:CAS:528:DC%2BD1cXlvVSmur8%3D (Pubitemid 351693227)
90. PS Kim TD Armstrong H Song ME Wolpoe V Weiss EA Manning, et al. 2008 Antibody association with HER-2/neu-targeted vaccine enhances CD8 T cell responses in mice through Fc-mediated activation of DCs Journal of Clinical Investigation 118 1700 1711 18398507 1:CAS:528:DC%2BD1cXlsF2ntLs%3D (Pubitemid 351632374)
91. B Clemenceau R Vivien M Berthomé N Robillard N Garand G Gallot, et al. 2008 Effector memory alphabeta T lymphocytes can express Fcgamma RIIIa and mediate antibody-dependent cellular cytotoxicity Journal of Immunology 180 5327 5334 1:CAS:528:DC%2BD1cXkt1arsb8%3D
92. R Bargou E Leo G Zugmaier M Klinger M Goebeler S Knop, et al. 2008 Tumor regression in cancer patients by very low doses of a T cell-engaging antibody Science 321 974 977 18703743 1:CAS:528:DC%2BD1cXpslWru70%3D
93. JS de Bono SY Rha J Stephenson BC Schultes P Monroe GS Eckhardt, et al. 2004 Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunity Annals of Oncology 15 1825 1833 15550589 (Pubitemid 40012249)
94. C Taylor D Hershman N Shah N Suciu-Foca DP Petrylak R Taub, et al. 2007 Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy Clinical Cancer Research 13 5133 5143 17785568 1:CAS:528: DC%2BD2sXpvFGqsrk%3D (Pubitemid 47502081)
95. N Selenko O Maidic S Draxier A Berer U Jäger W Knapp, et al. 2001 CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cells Leukemia 15 1619 1626 11587221 1:CAS:528:DC%2BD3MXnvF2mur0%3D (Pubitemid 32994682)
96. N Selenko O Majdic U Jäger C Sillaber J Stöckl W Knapp 2002 Cross-priming of cytotoxic T cells promoted by apoptosis-inducing tumor cell reactive antibodies? Journal of Clinical Immunology 22 124 130 12078853 1:CAS:528:DC%2BD38Xks1Ghsbs%3D (Pubitemid 34596935)
97. Z Gadri T Kukulansky E Bar-Or J Haimovich N Hollander 2009 Synergistic effect of dendritic cell vaccination and anti-CD20 antibody treatment in the therapy of murine lymphoma Journal of Immunotherapy 32 333 340 19342972 1:CAS:528:DC%2BD1MXkvVGmsb4%3D
98. TA Davis AJ Grillo-López CA White P McLaughlin MS Czuczman BK Link, et al. 2000 Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment 3143 18 3135 3143 1:CAS:528:DC%2BD3cXntVCgsbo%3D
99. JD Hainsworth S Litchy HA Burris DC Scullin SW Corso DA Yardley, et al. 2002 Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma Journal of Clinical Oncology 20 4261 4267 12377971 1:CAS:528:DC%2BD38XnsFyqsLk%3D (Pubitemid 35191030)
100. WK Weng D Czerwinski R Levy 2007 Humoral immune response and immunoglobulin G Fc receptor genotype are associated with better clinical outcome following idiotype vaccination in follicular lymphoma patients regardless of their response to induction chemotherapy Blood 109 951 953 17032925 1:CAS:528:DC%2BD2sXjtFersbk%3D (Pubitemid 46220638)
101. SP Bohen OG Troyanskaya O Alter R Warnke D Botstein PO Brown, et al. 2003 Variation in gene expression patterns in follicular lymphoma and the response to rituximab Proceedings of the National Academy of Sciences of the United States of America 100 1926 1930 12571354 1:CAS:528:DC%2BD3sXhsFGrs7s%3D (Pubitemid 36254550)
102. JP Jais C Haioun TJ Molina DS Rickman A de Reynies F Berger, et al. 2008 Groupe d'Etude des Lymphomes de l'Adulte: the expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab Leukemia 22 1917 1924 18615101 1:CAS:528:DC%2BD1cXht1Cms77O
103. N di Gaetano E Cittera R Nota A Vecchi V Grieco E Scanziani, et al. 2003 Complement activation determines the therapeutic activity of rituximab in vivo Journal of Immunology 171 1581 1587 (Pubitemid 36900094)
104. + T cells Immunity 22 371 383 15780993 1:CAS:528:DC%2BD2MXjt1Ohtr4%3D (Pubitemid 40387478)
105. A Perez-Diez NT Joncker K Choi WFN Chan CC Anderson O Lantz, et al. 2007 CD4 cells can be more efficient at tumor rejection than CD8 cells Blood 109 5346 5354 17327412 1:CAS:528:DC%2BD2sXmslOrsLc%3D (Pubitemid 46890556)
106. M Khalil RH Vonderheide 2007 Anti-CD40 agonist antibodies: preclinical and clinical experience Update on Cancer Therapeutics 2 61 65 19587842 (Pubitemid 47393664)
107. R Advani A Forero-Torres RR Furman JD Rosenblatt A Younes H Ren, et al. 2007 Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma Journal of Clinical Oncology 27 4371 4377
108. AA Sarnaik JS Weber 2009 Recent advances using anti-CTLA-4 for the treatment of melanoma Cancer Journal 15 169 173 1:CAS:528:DC%2BD1MXot12rsL8%3D
109. MJ Gough CE Ruby WL Redmond B Dhungel A Brown AD Weinberg 2008 OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor Cancer Research 68 5206 5215 18593921 1:CAS:528:DC%2BD1cXnvFyjs7o%3D
110. R Berger R Rotem-Yehudar G Slama S Landes A Kneller M Leiba, et al. 2008 Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies Clinical Cancer Research 14 3044 3051 18483370 1:CAS:528:DC%2BD1cXmtVCmtbw%3D
111. B Coiffier E Lepage J Briere R Herbrecht H Tilly R Bouabdallah, et al. 2002 CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma The New England Journal of Medicine 346 235 242 11807147 1:CAS:528:DC%2BD38XmslGgsw%3D%3D (Pubitemid 34438862)
112. R Forstpointner M Dreyling R Repp S Hermann A Hänel B Metzner, et al. 2004 German Low-Grade Lymphoma Study Group: the addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group Blood 104 3064 3071 15284112 1:CAS:528:DC%2BD2cXhtVWhur%2FE (Pubitemid 39517009)
113. B Coiffier C Thieblemont E van Den Neste G Lepeu I Plantier S Castaigne, et al. 2010 Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte Blood 116 2040 2045 20548096 1:CAS:528:DC%2BC3cXht1KisbbI
114. JA Bonner PM Harari J Giralt RB Cohen CU Jones RK Sur, et al. 2010 Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival The Lancet Oncology 11 21 28 19897418 1:CAS:528:DC%2BC3cXjslKktA%3D%3D
115. CG Willett DG Duda E di Tomaso Y Boucher M Ancukiewicz DV Sahani, et al. 2009 Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study Journal of Clinical Oncology 27 3020 3026 19470921 1:CAS:528: DC%2BD1MXoslyisLY%3D
116. JL Gulley PM Arlen A Bastian S Morin J Marte P Beetham, et al. 2005 Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer Clinical Cancer Research 11 3353 3362
117. RE Roses M Xu GK Koski BJ Czerniecki 2008 Radiation therapy and Toll-like receptor signaling: implications for the treatment of cancer Oncogene 27 200 207 18176601 1:CAS:528:DC%2BD1cXitl2hsA%3D%3D
118. L Zitvogel G Kroemer 2009 Anticancer immunochemotherapy using adjuvants with direct cytotoxic effects Journal of Clinical Investigation 119 2127 2130 19620780 1:CAS:528:DC%2BD1MXpsFCltbY%3D
119. E Kimby J Jurlander C Geisler H Hagberg H Holte T Lehtinen, et al. 2008 Nordic Lymphoma Group: long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: a randomized phase II study from the Nordic Lymphoma Group Leukemia & Lymphoma 49 102 112 1:CAS:528:DC%2BD1cXnsFequw%3D%3D (Pubitemid 351146889)
120. G Cartron L Zhao-Yang M Baudard T Kanouni V Rouillé P Quittet, et al. 2008 Granulocyte-macrophage colony- stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma: results of a phase II study Journal of Clinical Oncology 26 2725 2731 18427151 1:CAS:528: DC%2BD1cXnvVOhsbk%3D
121. KD Khan C Emmanouilides DM Benson D Hurst P Garcia G Michelson, et al. 2006 A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma Clinical Cancer Research 12 7046 7053 17145827 1:CAS:528:DC%2BD28Xht1Kns7nM (Pubitemid 44974502)
122. WW Overwijk MR Theoret NP Restifo 2000 The future of interleukin-2: enhancing therapeutic anticancer vaccines The Cancer Journal from Scientific American 6 576 580
123. + regulatory T cells European Journal of Immunology 38 1643 1653 18493984 1:CAS:528:DC%2BD1cXnsF2hu7s%3D
124. Park, S. G., Jiang, Z., Mortenson, E. D., Deng, L., Radkevich-Brown, O., Yang, X., et al. (2010). The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell, 18, 160-170.